Pair production of heavy charged gauge bosons in pppp collisions at LHC

Two opposite charged new heavy gauge boson pair production at the Large Hadron Collider (LHC) is presented in this paper. These bosons are known as $W^{'}$ boson due to the reason that it is the heavy version of Standard Model's weak force carrier, the $W$ boson. The production cross section and decay width in proton-proton ($pp$) collision at \sqrts~= 8 TeV are calculated for different masses and coupling strengths of $W^{'}$. Efficiencies for different signal regions and branching ratios for different decay channels are computed. In this study, the pair production ($W^{'^{+}}W^{'^{-}}$) is considered in emerging new physics as a result of $pp$ collision at \sqrts~= 8 TeV at the LHC with final state containing two tau ($\tau$) leptons and two neutrinos (each $W^{'}$ decay to $\tau$ and its neutrino). The event selection efficiency similar to the CMS experiment is used for the mass of $W^{'}$ to set lower limits for different coupling strengths of $W^{'}$ and results are presented in this work. For heavy gauge bosons, when coupling strength is similar to that of Standard Model's $W$ boson, the mass of $W^{'}$ below 305 GeV are excluded at confidence level of $95\%$.Comment: 21 pages, 16 figure

Efficacy and Tolerability of Isocitrate Dehydrogenase Inhibitors in Patients With Acute Myeloid Leukemia: A Systematic Review of Clinical Trials

BACKGROUND: Acute myeloid leukemia (AML) is a hematological malignancy due to anomalous differentiation and proliferation of hematopoietic stem cells with myeloid blast buildup. Induction chemotherapy is considered the first line of treatment in most patients with AML. However, targeted therapy in the form of FLT-3, IDH, BCL-2, and immune checkpoint inhibitors, can be considered as the first line depending on their molecular profile, resistance to chemotherapy, comorbidities, etc. This review aims to assess the tolerability and efficacy of isocitrate dehydrogenase (IDH) inhibitors in AML. METHODS: We searched Medline, WOS, Embase, and clinicaltrials.gov. PRISMA guidelines were followed in this systematic review. 3327 articles were screened, and 9 clinical trials (N = 1119) were included. RESULTS: In randomized clinical trials (RCTs), objective response (OR) was reported in 63-74% of the patients with IDH inhibitors + azacitidine as compared to 19-36 % of the patients with azacitidine monotherapy in newly diagnosed (ND) medically unfit patients. Survival rates were significantly improved with the use of ivosidenib. OR was reported in 39.1-46 % of the patients who relapsed/refractory to chemotherapy. ≥Grade 3 IDH differentiation syndrome and QT prolongation were reported in 3.9-10 % and 2-10 % of the patients, respectively. CONCLUSION: IDH inhibitors (ivosidenib for IDH-1 and enasidenib for IDH-2) are safe and effective in treating ND medically unfit or relapsed refractory patients with IDH mutation. However, no survival benefit was reported with enasidenib. More randomized multicenter double-blinded clinical studies are needed to confirm these results and compare them with other targeting agents